RepRegen reports 3-month data from study of StronBone bioactive glass with Strontium

RepRegen™, the 'smart biomaterials' company previously known as BioCeramic Therapeutics, announced today that three-month data from an in vivo study of its StronBone™ bioactive glass with Strontium demonstrated that it can generate bone quality in and around defects that appears by analytical tests to be significantly superior to a standard bone void filler in the control defect.

“But of keen interest to RepRegen is not only that this sector is enormous and growing rapidly but also that it is extremely fragmented. Consequently, we expect that RepRegen will have numerous sales and out-licensing opportunities.”

Specifically, the three-month data demonstrated that:

• The bone in the defect was significantly stiffer—68%—in the StronBone defect than in the control defect; and,
• The bone in the defect was significantly denser—41%—in the StronBone defect than in the control defect.

The in vivo and analytical study was conducted at the Institute of Orthopaedics and Musculoskeletal Science at University College London (UCL) by principal investigator Professor Allen Goodship, Professor of Orthopaedic Sciences and Director of the Institute, who will be submitting the data for publication.

"The results of this study underscore why we believe our platform has the potential to dramatically enhance the repair and regeneration of hard tissue, such as bone," said Ian Brown, RepRegen's CEO. "These results also fortify our plans to begin commercialization of the first product from our hard tissue platform in 2010."

"The worldwide market for the orthopaedic biomaterials sector is expected to soar to $8.8 billion by 2012," added RepRegen's Chairman, Dr. Stephen Rietiker. "But of keen interest to RepRegen is not only that this sector is enormous and growing rapidly but also that it is extremely fragmented. Consequently, we expect that RepRegen will have numerous sales and out-licensing opportunities."

Earlier this year, an in vitro study presented at the 56th Annual Meeting of the Orthopaedic Research Society (ORS) demonstrated that RepRegen's patented Strontium-based bioactive glass platform enhances cellular attraction of osteoblasts to the matrix.